VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31

VERACYTE, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$43.80+0.68 (+1.58%)

Close on Oct 19, 2026

Market cap: $3.59B
P/E (TTM): 31.3
Dividend yield: –

VERACYTE, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	517	446	361	297	220	117	120	92	72	65	50	38	22	12	2.65
Cost of Revenue	–	–	–	–	–	–	36	33	28	25	21	17	13	7.58	2.93
Gross Profit	363	298	230	176	–	–	84	59	44	40	28	22	9.28	4.04	-0.28
Research & Development	71	69	57	41	30	17	15	15	14	15	13	9.80	7.81	6.61	6.68
Selling, General & Admin	211	206	188	171	181	89	83	65	55	52	48	41	25	16	8.31
Selling & Marketing	100	95	101	98	80	52	54	41	32	28	25	22	13	8.45	2.93
General & Administrative	111	111	86	73	101	37	29	24	23	24	23	19	12	7.92	5.37
Operating Expenses	–	–	–	–	–	–	–	114	98	94	83	67	45	31	18
Total Costs & Expenses	305	282	315	217	301	153	135	114	98	–	–	–	–	–	–
Operating Income	58	16	-86	-41	-82	-35	-15	-22	-27	-29	-33	-29	-23	-19	-15
Interest Expense	–	–	–	–	–	0.23	0.68	1.96	4.94	2.76	0.38	0.44	0.23	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	0.01	0.00	0.00
Other Non-Operating Income	10	9.60	9.18	4.65	0.25	0.48	2.53	1.20	0.48	0.20	0.14	0.07	-2.17	0.28	0.82
Asset Impairment Charges	21	3.37	68	3.32	0	0	0	0	0	0	0	0	0	–	0.22
Gain (Loss) on Sale of Assets	-0.02	-0.20	-0.27	-0.21	0	0	0.02	0	-0.01	-0.01	0	0	–	–	–
Pretax Income	68	26	-77	-36	-82	-35	-13	-23	-31	-31	-34	-29	-26	-19	-14
Income Tax Expense	1.85	1.61	-2.21	0.13	-6.09	0	0	0	0	0	0	0	0	–	–
Net Income	66	24	-74	-37	-76	-35	-13	-23	–	–	–	–	–	–	–
Net Income to Common	66	24	-74	-37	–	–	-13	-23	-31	-31	-34	-29	-26	-19	-14
EPS (Basic)(per share)	0.84	0.32	-1.02	-0.51	-1.11	-0.66	-0.27	-0.62	-0.91	-1.09	-1.30	-1.36	-6.15	-28.68	-24.90
EPS (Diluted)(per share)	0.82	0.31	-1.02	-0.51	-1.11	-0.66	-0.27	-0.62	-0.91	-1.09	-1.30	-1.36	-6.15	-28.68	-24.90
Shares Outstanding (Basic, Weighted)(shares)	79	76	73	72	68	53	46	37	34	29	26	22	4.16	0.65	0.58
Shares Outstanding (Diluted, Weighted)(shares)	81	78	73	72	68	53	46	37	34	29	26	22	4.16	0.65	0.58
EBITDA	79	40	-59	-15	-62	-27	-11	-18	-23	-25	-31	-28	-22	-18	-15

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.7%
Operating margin: 18.8%
Net margin: 20.4%
Return on equity, FY2025: 5.3%

Financial strength

Current ratio: 9.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 477.4%

Valuation

P/E ratio: 31.3
Price to sales: 6.40
Price to book: 2.59
Dividend yield: –